Immunalgia Therapeutics is proud to announce a significant breakthrough in our mission to transform the treatment of chronic pain conditions. Our lead candidate and first-in-class multitarget drug, IMT-504, has successfully completed a Phase I clinical trial and in the next coming days the final report will be presented to the argentine regulatory office. Our immediate goal at present is to explore the efficiency of IMT 504for the treatment of Complex Regional Pain Syndrome (CRPS) — a debilitating and currently underserved neurological condition.
This marks a pivotal step forward not only for our pipeline but also for the broader field of immunomodulatory pain therapeutics. The Phase I trial demonstrated a favorable safety and tolerability profile in healthy volunteers, reinforcing the potential of IMT-504 as a novel, multi-targeted approach to pain management.
CRPS is a complex, chronic condition with limited therapeutic options and a profound impact on quality of life. IMT-504 represents a new therapeutic paradigm, designed to modulate immune pathways involved in neuroinflammation and pain sensitization, without the harmful side effects associated with traditional analgesics or immunosuppressants.
We are now working on the design and preparing to initiate Phase II clinical trial by the begining of 2026, bringing us one step closer to offering patients a safer, more effective treatment alternative.
Stay tuned as we continue advancing toward our goal of delivering breakthrough solutions for chronic pain through cutting-edge immunological science.
